Niagen Bioscience Inc (NAGE)

Niagen Bioscience Inc at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Niagen Bioscience Inc (NAGE) is a Biotechnology company based in US with a market capitalization of $278M. Revenue grew 29.9% year-over-year and the company generated $13.1M in free cash flow. This page tracks NAGE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 104 employees · IPO Jun 24, 2015

Valuation

Valuation & price

$3.65as of May 17, 2026· -64.4% vs 52w high

17.9

P/E ratio

Latest-FY diluted EPS

3.63

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$10.24$6.72$3.21Jul 25Jan 26Jul 26
$3.1952-week range$10.26
Loading valuation history…

Fundamentals

Key fundamentals

$278M

Market cap

29.9%

Revenue growth (YoY)

64.3%

Gross margin

$13.1M

Free cash flow (USD)

-$62M

Net debt

Net cash position

-7.3%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$21.7M$129.4M

Free cash flow by year

20162025

-$4.7M$13.1M

Gross margin by year

20212025

61.5%64.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJun 29, 2026Filing

    Annual Meeting Results

  • FinancingJun 26, 2026Filing

    Securities Registration

  • Quarterly reportMay 6, 2026Filing

    10-Q Filed

  • 8-K eventMay 6, 2026Filing

    Earnings Release

Questions

Frequently asked questions

What is Niagen Bioscience Inc's market cap?

Niagen Bioscience Inc (NAGE) has a market capitalization of $278M.

What is NAGE's P/E ratio?

NAGE trades at a price-to-earnings ratio of 17.9, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is NAGE's price-to-book (P/B) ratio?

NAGE trades at 3.63 times book value per share.

Are insiders buying NAGE stock?

SEC Form 4 filings show no open-market insider buys at Niagen Bioscience Inc in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.